van Houte Hans

Chief Financial OfficerNurix Therapeutics, Inc. (NRIX) · full profile →Form 4 · filed Jul 30, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$67K
Net Open-Market Flow
-$67K
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 30, 2026Option exercise(M)4K$041K
Jul 30, 2026Option exercise(M)3K$044K
Jul 30, 2026Option exercise(M)4K$048K
Jul 30, 2026Sell(S)3K$23.38$67K45K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 30, 2026Option exercise(M)4K$011K
Jul 30, 2026Option exercise(M)3K$020K
Jul 30, 2026Option exercise(M)4K$039K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001817217-26-000010) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.